Treatment of Yeast in Fecal Analysis
Critical Distinction: Colonization vs. Infection
- The Infectious Diseases Society of America explicitly states that growth of Candida from any site requires clinical correlation with signs and symptoms of actual infection before initiating therapy 1
- Treatment is NOT indicated for asymptomatic patients with yeast in stool, even in ICU or immunocompromised patients, unless there is clear evidence of invasive infection 2, 1
When Treatment IS Indicated
- Antifungal therapy should only be considered when yeast in stool is accompanied by recent abdominal surgery with anastomotic leaks 3, 4, 5
- Antifungal therapy should only be considered when yeast in stool is accompanied by recurrent gastroduodenal perforations (40% develop intra-abdominal candidiasis) 3, 6, 5
- Antifungal therapy should only be considered when yeast in stool is accompanied by acute necrotizing pancreatitis 3, 4, 5
- Antifungal therapy should only be considered when yeast is isolated from normally sterile intra-abdominal specimens (operative specimens or drains placed within 24 hours) PLUS clinical signs of infection 2, 3, 6, 5
Specific Clinical Situations Requiring Empiric Therapy
- Patients with septic shock in community-acquired intra-abdominal infections require empiric antifungal therapy according to the World Journal of Emergency Surgery 7
- Patients with post-operative infections where yeast presence is associated with poor prognosis (mortality >60% without source control) require empiric antifungal therapy 7
Treatment Algorithm When Therapy IS Warranted
- Adequate drainage and/or debridement is mandatory and more important than antifungal selection 3, 4, 5, 8
- Inadequate source control results in treatment failure regardless of appropriate antifungal therapy 7, 8
- Echinocandins are preferred first-line agents for critically ill patients or those with septic shock 8, 1
- Fluconazole 400 mg (6 mg/kg) daily is acceptable if the isolate is susceptible 8, 1
Step-Down Therapy and Duration of Therapy
- After clinical improvement and confirmation of susceptible Candida species, transition to fluconazole 400-800 mg daily 8, 1
- De-escalation within 5 days is safe and not associated with increased mortality 7
- Continue therapy for 2-3 weeks based on clinical response and adequacy of source control 7, 8
Common Pitfalls to Avoid
- Do NOT treat asymptomatic yeast in stool - this represents colonization 2, 1
- Do NOT obtain swabs from superficial wounds or catheters in place >24 hours - these provide no useful information 2, 3, 6, 5
- Do NOT delay source control - mortality exceeds 60% in septic shock without adequate drainage/debridement 7, 8
- Do NOT use fluconazole empirically in critically ill patients without knowing susceptibility patterns, as C. glabrata resistance is common 7, 8
- Do NOT stop therapy prematurely before complete resolution of infection 8
Special Considerations
- Blood cultures are often negative (even with invasive disease), so negative cultures do not rule out intra-abdominal candidiasis 2, 3, 6, 5
- β-D-glucan testing may help distinguish colonization from invasive disease (72% positive predictive value, 80% negative predictive value) but is not routinely required 2, 3, 6
Treatment of Intra-Abdominal Candidiasis
Treatment Duration and Candida Species Considerations
- The Infectious Diseases Society guideline recommends treating candidemia without persistent fungemia or metastatic complications for at least 14 days following resolution of symptoms or following last positive culture, whichever is longer, and treatment duration for intra-abdominal candidiasis should be continued for 2-3 weeks based on clinical response and adequacy of source control 9
- For C. albicans, fluconazole is appropriate for susceptible isolates 9
- For C. krusei, echinocandin or lipid formulation amphotericin B is recommended due to inherent resistance to fluconazole 9
- For C. parapsilosis, fluconazole is preferred if susceptible, while echinocandins have reduced activity 9